Compounds > gamma-aminobutyric acid
Page last updated: 2024-10-16

gamma-aminobutyric acid and Syndrome

gamma-aminobutyric acid has been researched along with Syndrome in 93 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day."9.10Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002)
"We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol."9.05Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. ( Lew, TY; Tollefson, G, 1983)
"Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain."8.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates."8.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain."8.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule."8.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
" Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes."8.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain."8.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain."8.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome."7.71Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002)
" I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride."7.68Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990)
"Gabapentin was given in three divided doses, initially titrated to 900 mg/day over 3 days, followed by two further increases, to a maximum of 2400 mg/day if required by the end of week 5."6.70Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002)
"Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day."6.69Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998)
"Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain."6.46Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia."6.46Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
" Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications."6.44Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007)
"It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia."6.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes."6.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule."6.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain."6.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated."6.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes."6.41Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000)
"Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons."6.41Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000)
"Charles Bonnet syndrome is a condition characterised by the presence of visual hallucinations in patients having visual impairment most commonly reported in the seventh decade."5.39Pregabalin in the treatment of Charles Bonnet syndrome. ( Bokdawala, RA; Sawant, NS, 2013)
"Gabapentin (Neurontin) was then started with improvement at 1800 mg per day."5.31SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000)
"Cramps were mainly nocturnal and also precipitated by walking; a previous treatment with carbamazepine did not improve the symptoms."5.30A case of myokymia-cramp syndrome successfully treated with gabapentin. ( Cardinali, P; Parisi, L; Pierelli, F; Rossi, P; Serrao, M; Tramutoli, R, 1998)
" Gabapentin therapy proved to be very satisfactory in relieving muscular cramps with a relatively low dosage (600 mg/day) and without any remarkable side effects."5.30A case of myokymia-cramp syndrome successfully treated with gabapentin. ( Cardinali, P; Parisi, L; Pierelli, F; Rossi, P; Serrao, M; Tramutoli, R, 1998)
"Treatment by progabide, a GABA-agonist, was successful in one case: a gradual improvement was observed during four weeks and the movements have now disappeared after six months of progabide therapy."5.27[Progabide treatment of a case of the syndrome of painful legs and moving toes]. ( Bovier, P; Hilleret, H; Tissot, R, 1985)
"A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day."5.10Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002)
"We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol."5.05Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. ( Lew, TY; Tollefson, G, 1983)
"Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates."4.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain."4.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain."4.86Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule."4.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain."4.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain."4.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
" Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes."4.82Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"We report a case of red scrotal syndrome responding to oral gabapentin, a neuropathic mediator that is commonly used in the treatment of primary erythromelalgia."3.74Case reports: red scrotal syndrome: a localized phenotypical expression of erythromelalgia. ( English, JC; Prevost, N, 2007)
"Aromatic anticonvulsant agents such as carbamazepine and phenytoin can induce anticonvulsant hypersensitivity syndrome (AHS) at a frequency of 1 in 10,000 to 1 in 1,000 treated patients."3.73Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. ( Bröcker, EB; Pfeuffer, P; Raith, P; Seitz, CS; Trautmann, A, 2006)
"Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin."3.72[Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003)
"Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome."3.71Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002)
"Seizures in a term infant with Ohtahara syndrome, associated with polymicrogyria, and a pre-term neonate with similar clinical features, failed to respond to conventional anticonvulsants, but were controlled with vigabatrin monotherapy."3.69Vigabatrin monotherapy in resistant neonatal seizures. ( Barwick, DD; Baxter, PS; Gardner-Medwin, D; Ince, P; Livingston, J; Murdoch-Eaton, D, 1995)
" I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride."3.68Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990)
"The lumbar cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 27 patients with epilepsy, another three epileptic patients with status epilepticus and three epileptic patients with chronic cerebellar ataxia."3.67GABA levels in cerebrospinal fluid of patients with epilepsy. ( Hosokawa, K; Kugoh, T; Ogawa, N; Otsuki, S; Takahashi, S; Yamamoto, M, 1985)
"We measured gamma-aminobutyric acid (GABA) receptor binding in the cerebellar cortex of 14 patients with dominantly-inherited cerebellar ataxias."3.66Increased GABA receptor binding in dominantly-inherited cerebellar ataxias. ( Hornykiewicz, O; Kish, SJ; Perry, TL, 1983)
"Both AB+AA and AA can relieve insomnia symptoms, but a stronger long-term effect were observed for AB+AA."3.11Effect of Auricular Acupoint Bloodletting plus Auricular Acupressure on Sleep Quality and Neuroendocrine Level in College Students with Primary Insomnia: A Randomized Controlled Trial. ( Chen, H; Huo, YX; Liu, DN; She, YF; Shi, XL; Sun, H; Wu, JA; Yuan, XR; Zhang, MJ, 2022)
"Patients with diabetic polyneuropathy were examined to study their biological age, rate of aging and pain syndrome."2.76[Biological age and the pain syndrome at diabetic polyneuropathy]. ( Emel'ianov, VV; Galkin, VV; Nesterova, MV, 2011)
"Gabapentin was given in three divided doses, initially titrated to 900 mg/day over 3 days, followed by two further increases, to a maximum of 2400 mg/day if required by the end of week 5."2.70Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002)
"Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day."2.69Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998)
"Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia."2.46Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain."2.46Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010)
"Dizziness is not a unique clinical picture, but rather is the unspecific symptom of numerous diseases."2.44[Frequently occurring forms of dizziness and their treatment]. ( Thömke, F, 2007)
" Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications."2.44Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007)
"It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia."2.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated."2.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes."2.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain."2.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule."2.42Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003)
"Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons."2.41Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000)
"Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes."2.41Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000)
"Knowledge of these syndromes has important treatment and prognostic implications, which usually extend into adulthood."2.41Adolescent seizures and epilepsy syndromes. ( Kim, HL; Wheless, JW, 2002)
"The characteristic clinical history, seizure semiology, and magnetic resonance imaging findings have allowed a discrete epilepsy syndrome to be established."2.41Adolescent seizures and epilepsy syndromes. ( Kim, HL; Wheless, JW, 2002)
"Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function."2.36Pharmacology of GABA. ( Meldrum, B, 1982)
"Here we report a case of possible small fiber neuropathy associated with hantavirus infection, in a patient who survived HCPS."1.46A neuropathic pain syndrome associated with hantavirus infection. ( Anderson, D; Beecher, G; Bridgland, L; Power, C; Zochodne, DW, 2017)
"Persistent and treatment-resistant neuropathic pain may be a prominent feature in hantavirus-associated peripheral neuropathy."1.46A neuropathic pain syndrome associated with hantavirus infection. ( Anderson, D; Beecher, G; Bridgland, L; Power, C; Zochodne, DW, 2017)
"Charles Bonnet syndrome is a condition characterised by the presence of visual hallucinations in patients having visual impairment most commonly reported in the seventh decade."1.39Pregabalin in the treatment of Charles Bonnet syndrome. ( Bokdawala, RA; Sawant, NS, 2013)
"Pelvic pain was detected 5 days after antigen instillation and was sustained beyond 30 days, indicating the development of chronic pain."1.35Experimental autoimmune prostatitis induces chronic pelvic pain. ( Rudick, CN; Schaeffer, AJ; Thumbikat, P, 2008)
"Neuropathic and/or neuralgic facial pain occurred in 50% (n = 7)."1.35The trigeminal trophic syndrome: an unusual cause of face pain, dysaesthesias, anaesthesia and skin/soft tissue lesions. ( Garza, I, 2008)
"We report the successful management of anesthesia in a patient with stiff-person syndrome (SPS) undergoing a thymectomy using a volatile anesthetic combined with epidural anesthesia."1.34Considerations for general anesthesia combined with epidural anesthesia in a patient with stiff-person syndrome. ( Hara, K; Horishita, T; Sata, T; Yamamoto, K, 2007)
"Paroxysmal autonomic instability with dystonia, an under-recognized and poorly understood phenomenon of episodic central dysautonomia is associated with various cerebral insults."1.34Paroxysmal autonomic instability with dystonia. ( Lim, CC; Srinivasan, S; Thirugnanam, U, 2007)
"This syndrome is accompanied by fever, rash, lymphadenopathy, eosinophilia and affects parenchymal organs."1.32[Anticonvulsant hypersensitivity syndrome]. ( Papp, Z; Török, L, 2004)
"SUNCT, a still relatively unknown headache syndrome, is characterized by attacks of periorbital pain with accompanying ipsilateral autonomic symptoms."1.32[Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003)
"Gabapentin (Neurontin) was then started with improvement at 1800 mg per day."1.31SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000)
"Cramps were mainly nocturnal and also precipitated by walking; a previous treatment with carbamazepine did not improve the symptoms."1.30A case of myokymia-cramp syndrome successfully treated with gabapentin. ( Cardinali, P; Parisi, L; Pierelli, F; Rossi, P; Serrao, M; Tramutoli, R, 1998)
" Gabapentin therapy proved to be very satisfactory in relieving muscular cramps with a relatively low dosage (600 mg/day) and without any remarkable side effects."1.30A case of myokymia-cramp syndrome successfully treated with gabapentin. ( Cardinali, P; Parisi, L; Pierelli, F; Rossi, P; Serrao, M; Tramutoli, R, 1998)
"Treatment by progabide, a GABA-agonist, was successful in one case: a gradual improvement was observed during four weeks and the movements have now disappeared after six months of progabide therapy."1.27[Progabide treatment of a case of the syndrome of painful legs and moving toes]. ( Bovier, P; Hilleret, H; Tissot, R, 1985)
"Stiff-man syndrome is a rare disorder of the central nervous system consisting of progressive, fluctuating muscle rigidity with painful spasms."1.27Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. ( Comi, GC; De Camilli, P; Denis-Donini, S; Folli, F; Pozza, G; Solimena, M; Vicari, AM, 1988)
"Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss."1.26Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979)

Research

Studies (93)

TimeframeStudies, this research(%)All Research%
pre-199026 (27.96)18.7374
1990's12 (12.90)18.2507
2000's32 (34.41)29.6817
2010's21 (22.58)24.3611
2020's2 (2.15)2.80

Authors

AuthorsStudies
Hines, DJ1
Contreras, A1
Garcia, B1
Barker, JS1
Boren, AJ1
Moufawad El Achkar, C1
Moss, SJ1
Hines, RM1
Chen, H1
Zhang, MJ1
Wu, JA1
She, YF1
Yuan, XR1
Huo, YX1
Sun, H1
Liu, DN1
Shi, XL1
Bögli, SY1
Afthinos, M1
Huang, MY1
Anderson, D1
Beecher, G1
Power, C1
Bridgland, L1
Zochodne, DW1
Niturad, CE1
Lev, D1
Kalscheuer, VM1
Charzewska, A1
Schubert, J1
Lerman-Sagie, T1
Kroes, HY1
Oegema, R1
Traverso, M1
Specchio, N1
Lassota, M1
Chelly, J1
Bennett-Back, O1
Carmi, N1
Koffler-Brill, T1
Iacomino, M1
Trivisano, M1
Capovilla, G1
Striano, P2
Nawara, M1
Rzonca, S1
Fischer, U1
Bienek, M1
Jensen, C1
Hu, H1
Thiele, H1
Altmüller, J1
Krause, R1
May, P1
Becker, F1
Balling, R1
Biskup, S1
Haas, SA1
Nürnberg, P1
van Gassen, KLI1
Lerche, H1
Zara, F1
Maljevic, S1
Leshinsky-Silver, E1
Arellano, AL1
Martin-Subero, M1
Monerris, M1
LLerena, A1
Farré, M1
Montané, E1
Harper, DE1
Ichesco, E1
Schrepf, A1
Halvorson, M1
Puiu, T1
Clauw, DJ1
Harris, RE1
Harte, SE1
Baizabal-Carvallo, JF1
Sawant, NS1
Bokdawala, RA1
Alexopoulos, H1
Dalakas, MC1
Rashiq, S1
Dick, BD1
Roldan, CJ1
Lesnick, JS1
Gregory, T1
Sangha, H1
Bleakney, R1
Nair, AG2
Shah, BR1
Gandhi, RA1
Alrawashdeh, O1
Garza, I1
Striano, S1
Coppola, A1
Romanelli, P1
Bar Ad, V1
Pal'tsev, AI1
Torgashov, MN1
Vorontsova, IuS1
Baiandina, EV1
Luniakina, SB1
Wierońska, JM1
Kusek, M1
Tokarski, K1
Wabno, J1
Froestl, W1
Pilc, A1
Lantos, PM1
Galkin, VV1
Nesterova, MV1
Emel'ianov, VV1
Mease, PJ1
Dundon, K1
Sarzi-Puttini, P2
Spaeth, M1
Rizzi, M1
Han, S1
Tai, C1
Westenbroek, RE1
Yu, FH1
Cheah, CS1
Potter, GB1
Rubenstein, JL1
Scheuer, T1
de la Iglesia, HO1
Catterall, WA1
Porta-Etessam, J2
Benito-Leon, J1
Martinez-Salio, A2
Berbel, A1
Hunt, CH1
Dodick, DW1
Bosch, EP1
Chen, B1
Stitik, TP1
Foye, PM1
Nadler, SF1
DeLisa, JA1
Serpell, MG1
Guéguen, A1
Guy, C1
Cartry, O1
Bouchou, K1
Gouilloud, S1
Cathébras, P1
Nicolas, X1
Vaillant, PY1
Bellard, S1
Backonja, M1
Glanzman, RL1
Neumeier, S1
Brinkschmidt, T1
Jensen, U1
BENEDETTI, GA1
SEMPREBENE, L1
Oefelein, MG1
Bayazit, Y1
Villarejo, A1
Camacho, A1
González De La Aleja, J1
Penas, M1
Papp, Z1
Török, L1
Yasuda, K1
Hiraoka, M1
Finucane, TE1
Seitz, CS1
Pfeuffer, P1
Raith, P1
Bröcker, EB1
Trautmann, A1
Barsukov, IN1
Kashin, AV1
Kostiuk, GP1
Srinivasan, S1
Lim, CC1
Thirugnanam, U1
Thömke, F1
Spiller, J1
Prevost, N1
English, JC1
Yamamoto, K1
Hara, K1
Horishita, T1
Sata, T1
Aizawa, H1
Owen, RT1
Rudick, CN1
Schaeffer, AJ1
Thumbikat, P1
Baillieux, H1
Verslegers, W1
Paquier, P1
De Deyn, PP2
Mariën, P1
Becker, RE1
Lal, H1
Bowser-Riley, F1
Angel, A1
Halsey, MJ1
Little, H1
Meldrum, BS1
Ross, JA1
Rostain, JC1
Wardley-Smith, B1
Perry, TL5
Nicklas, WJ1
Yamamoto, M2
Otsuki, S2
Miyake, K1
Namba, R1
Meldrum, B1
Kish, SJ1
Hornykiewicz, O1
Lew, TY1
Tollefson, G1
Sakai, T1
Hosokawa, S1
Shibasaki, H1
Goto, I1
Kuroiwa, Y1
Sonoda, H1
Murai, Y1
Arushanian, EB1
Dutov, AA1
Pokrovskaia, NIa1
Koval'skaia, SIa1
Ozeretskovskiĭ, NA1
Veĭsfeĭler, OIu1
Avrutskaia, IG1
Ermolina, LA1
Lahat, E1
Baxter, PS1
Gardner-Medwin, D1
Barwick, DD1
Ince, P1
Livingston, J1
Murdoch-Eaton, D1
Lin, JJ1
Chang, MK1
Blasi, C1
Jeanrenaud, B1
Vossler, DG1
Tanase, S1
Bélanger, S1
Coulombe, G1
Carmant, L1
Attal, N1
Brasseur, L1
Parker, F1
Chauvin, M1
Bouhassira, D1
Serrao, M1
Cardinali, P1
Rossi, P1
Parisi, L1
Tramutoli, R1
Pierelli, F1
Nicholson, B1
Graff-Radford, SB1
Derk, CT1
Cynwyd, B1
Engelborghs, S1
D'Hooge, R1
Paulig, M1
Mentrup, H1
Wheless, JW1
Kim, HL1
Hansen, S1
Currier, RD1
Berry, K1
Purdy, A1
Hahn, A1
Barnett, HJ1
Bratty, P1
Ahmad, D1
Lloyd, KG1
McGeer, EG1
Kryzhanovskiĭ, GN1
Aliev, MN1
Lupandin, VM1
Lando, LI1
Gromova, EA1
Kamenskaia, VM1
Zykov, MB1
Green, AR1
Tordoff, AF1
Bloomfield, MR1
Dubowitz, LM1
Bouza, H1
Hird, MF1
Jaeken, J1
Baekkeskov, S1
Aanstoot, HJ1
Christgau, S1
Reetz, A1
Solimena, M3
Cascalho, M1
Folli, F3
Richter-Olesen, H1
De Camilli, P2
Camilli, PD1
Sandyk, R1
Dunn, HG1
Ho, HH1
Crichton, JU1
Bovier, P1
Hilleret, H1
Tissot, R1
Denis-Donini, S1
Comi, GC1
Pozza, G1
Vicari, AM1
Takahashi, S1
Kugoh, T1
Hosokawa, K1
Ogawa, N1
Soyka, D1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311]Phase 240 participants (Anticipated)Interventional2021-05-03Recruiting
The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial[NCT00001550]Phase 120 participants Interventional1996-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

21 reviews available for gamma-aminobutyric acid and Syndrome

ArticleYear
The neurological syndromes associated with glutamic acid decarboxylase antibodies.
    Journal of autoimmunity, 2019, Volume: 101

    Topics: Autoantibodies; Autoimmune Diseases; Autoimmunity; Brain; Combined Modality Therapy; Disease Suscept

2019
Immunology of stiff person syndrome and other GAD-associated neurological disorders.
    Expert review of clinical immunology, 2013, Volume: 9, Issue:11

    Topics: Animals; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Biomarkers; Diseas

2013
Post-surgical pain syndromes: a review for the non-pain specialist.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2014, Volume: 61, Issue:2

    Topics: Age Factors; Amines; Analgesics; Anesthesia; Anesthetics; Anesthetics, Local; Animals; Chronic Pain;

2014
The syndrome gelastic seizures-hypothalamic hamartoma: severe, potentially reversible encephalopathy.
    Epilepsia, 2009, Volume: 50 Suppl 5

    Topics: Brain Neoplasms; Cognition Disorders; Epilepsies, Partial; gamma-Aminobutyric Acid; Hamartoma; Hypot

2009
Gabapentin for the treatment of cancer-related pain syndromes.
    Reviews on recent clinical trials, 2010, Volume: 5, Issue:3

    Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci

2010
Pharmacotherapy of fibromyalgia.
    Best practice & research. Clinical rheumatology, 2011, Volume: 25, Issue:2

    Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Cognition Disorders; Cyclopropanes; Duloxetine H

2011
Fibromyalgia and sleep.
    Best practice & research. Clinical rheumatology, 2011, Volume: 25, Issue:2

    Topics: Analgesics; Central Nervous System Sensitization; Chronic Pain; Cyclopropanes; Duloxetine Hydrochlor

2011
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
    Clinical therapeutics, 2003, Volume: 25, Issue:1

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu

2003
[Pantothenic acid].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 12

    Topics: Biological Assay; Biomarkers; Chromatography, High Pressure Liquid; Coenzyme A; Foot; gamma-Aminobut

2004
[Frequently occurring forms of dizziness and their treatment].
    MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2

    Topics: Amines; Anticonvulsants; Betahistine; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnosis, Differe

2007
Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
    Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:12

    Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Depression; Fatigue; Fibromyalgia; gamma-Am

2007
Pharmacological approaches to treatment of hemiballism and hemichorea.
    Brain research bulletin, 1983, Volume: 11, Issue:2

    Topics: Acetylcholine; Antipsychotic Agents; Basal Ganglia; Cerebrovascular Disorders; Chorea; Diazepam; Dop

1983
Amino acid metabolism in the central nervous system: role of glutamate dehydrogenase.
    Advances in neurology, 1984, Volume: 41

    Topics: Amino Acid Metabolism, Inborn Errors; Animals; Central Nervous System; Cerebellar Ataxia; Enzyme Act

1984
Pharmacology of GABA.
    Clinical neuropharmacology, 1982, Volume: 5, Issue:3

    Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep

1982
[Nigrostriatal system as a source of torsion extrapyramidal disorders (review)].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1980, Volume: 80, Issue:6

    Topics: 5-Hydroxytryptophan; Acetylcholine; Animals; Basal Ganglia Diseases; Cats; Caudate Nucleus; Corpus S

1980
[Vigabatrin in the treatment of pediatric epileptic syndrome].
    Harefuah, 1995, Mar-01, Volume: 128, Issue:5

    Topics: Anticonvulsants; Child; Epilepsy; gamma-Aminobutyric Acid; Humans; Syndrome; Vigabatrin

1995
Hemiballism-hemichorea and non-ketotic hyperglycaemia.
    Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:6

    Topics: Aged; Basal Ganglia Diseases; Chorea; Dementia, Multi-Infarct; Diabetes Complications; Female; gamma

1994
[Vitamin B6 dependency syndrome (vitamin B6 dependent seizures, convulsions)].
    Ryoikibetsu shokogun shirizu, 1998, Issue:19 Pt 2

    Topics: Biomarkers; Electroencephalography; gamma-Aminobutyric Acid; Humans; Infant, Newborn; Prognosis; Pyr

1998
Gabapentin use in neuropathic pain syndromes.
    Acta neurologica Scandinavica, 2000, Volume: 101, Issue:6

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma

2000
Pathophysiology of epilepsy.
    Acta neurologica Belgica, 2000, Volume: 100, Issue:4

    Topics: Adult; Animals; Anticonvulsants; Autoimmune Diseases; Calcium; Catecholamines; Cell Movement; Child;

2000
Adolescent seizures and epilepsy syndromes.
    Epilepsia, 2002, Volume: 43 Suppl 3

    Topics: Adolescent; Age Factors; Brain; Child; Electroencephalography; Epilepsy; Epilepsy, Temporal Lobe; Es

2002

Trials

7 trials available for gamma-aminobutyric acid and Syndrome

ArticleYear
Effect of Auricular Acupoint Bloodletting plus Auricular Acupressure on Sleep Quality and Neuroendocrine Level in College Students with Primary Insomnia: A Randomized Controlled Trial.
    Chinese journal of integrative medicine, 2022, Volume: 28, Issue:12

    Topics: Acupressure; Acupuncture Points; Bloodletting; gamma-Aminobutyric Acid; Humans; Sleep Initiation and

2022
[Biological age and the pain syndrome at diabetic polyneuropathy].
    Advances in gerontology = Uspekhi gerontologii, 2011, Volume: 24, Issue:2

    Topics: Adult; Aging; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetic Neuropathies;

2011
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial.
    Pain, 2002, Volume: 99, Issue:3

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analysis of Variance; Chi-Square Distribution; Cyc

2002
Gabapentin for painful legs and moving toes syndrome.
    European neurology, 2004, Volume: 51, Issue:3

    Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Electromyography; Excitatory Amino Acid Antagon

2004
[The tebantin use in the complex therapy of pain syndrome during the mixed forms of alcoholic polyneuropathy].
    Voenno-meditsinskii zhurnal, 2006, Volume: 327, Issue:10

    Topics: Alcoholic Neuropathy; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe

2006
Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.
    Biological psychiatry, 1983, Volume: 18, Issue:12

    Topics: Brain; Chlorpromazine; Diazepam; Dopamine; Dyskinesia, Drug-Induced; Dystonia; Female; Fever; gamma-

1983
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study.
    European neurology, 1998, Volume: 40, Issue:4

    Topics: Acetates; Amines; Analgesics; Anticonvulsants; Central Nervous System Diseases; Cyclohexanecarboxyli

1998

Other Studies

65 other studies available for gamma-aminobutyric acid and Syndrome

ArticleYear
Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA
    Molecular psychiatry, 2022, Volume: 27, Issue:3

    Topics: Animals; gamma-Aminobutyric Acid; Humans; Intellectual Disability; Mice; Mutation; Receptors, GABA-A

2022
Effect of Gabapentin/Memantine on the Infantile Nystagmus Syndrome in the Zebrafish Model: Implications for the Therapy of Ocular Motor Diseases.
    Investigative ophthalmology & visual science, 2017, 06-01, Volume: 58, Issue:7

    Topics: Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Disease Models, Animal; Exci

2017
A neuropathic pain syndrome associated with hantavirus infection.
    Journal of neurovirology, 2017, Volume: 23, Issue:6

    Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acids; Gab

2017
Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features.
    Brain : a journal of neurology, 2017, Nov-01, Volume: 140, Issue:11

    Topics: Adolescent; Adult; Animals; Brain Diseases; Child; Child, Preschool; Cleft Palate; Developmental Dis

2017
Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result.
    Medicine, 2017, Volume: 96, Issue:45

    Topics: Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Drug Hypersensitivity; Female; Gabap

2017
Relationships between brain metabolite levels, functional connectivity, and negative mood in urologic chronic pelvic pain syndrome patients compared to controls: A MAPP research network study.
    NeuroImage. Clinical, 2018, Volume: 17

    Topics: Adult; Brain; Choline; Chronic Pain; Cross-Sectional Studies; Emotions; Female; gamma-Aminobutyric A

2018
Pregabalin in the treatment of Charles Bonnet syndrome.
    JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:4

    Topics: Analgesics; Diabetic Neuropathies; Diabetic Retinopathy; Female; gamma-Aminobutyric Acid; Hallucinat

2013
Phantom organ pain syndrome, a ghostly visitor to the ED.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:9

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Emergency Service, Hospital; Gabapentin; gam

2014
Spontaneous resolution of quadrilateral space syndrome: a case report.
    American journal of physical medicine & rehabilitation, 2015, Volume: 94, Issue:1

    Topics: Aged; Analgesics, Opioid; gamma-Aminobutyric Acid; Humans; Male; Naproxen; Nerve Compression Syndrom

2015
Seeing the unseen: Charles Bonnet syndrome revisited.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2015, Volume: 15, Issue:3

    Topics: Aged; Amines; Awareness; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H

2015
Painless legs and moving toes syndrome associated with a sacral Tarlov cyst: a case report.
    Journal of medical case reports, 2016, Mar-09, Volume: 10

    Topics: Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesias; Female; Gabapentin; gamma-Am

2016
The trigeminal trophic syndrome: an unusual cause of face pain, dysaesthesias, anaesthesia and skin/soft tissue lesions.
    Cephalalgia : an international journal of headache, 2008, Volume: 28, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Child; Cyclohexanecarboxylic Acids; Erythema; Fa

2008
[The role of combat stress in the development of chronic pain syndrom in veterans and its treatment by pantogam active].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:9

    Topics: Adult; Aged; Chronic Disease; Combat Disorders; gamma-Aminobutyric Acid; Humans; Male; Middle Aged;

2010
The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.
    British journal of pharmacology, 2011, Volume: 163, Issue:5

    Topics: Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Models, Animal; Dose-Response Relations

2011
Chronic Lyme disease: the controversies and the science.
    Expert review of anti-infective therapy, 2011, Volume: 9, Issue:7

    Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise

2011
Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission.
    Nature, 2012, Sep-20, Volume: 489, Issue:7416

    Topics: Animals; Anxiety; Autistic Disorder; Clonazepam; Epilepsies, Myoclonic; GABA Modulators; GABAergic N

2012
Gabapentin in the treatment of SUNCT syndrome.
    Headache, 2002, Volume: 42, Issue:6

    Topics: Acetates; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Am

2002
SUNCT responsive to gabapentin.
    Headache, 2002, Volume: 42, Issue:6

    Topics: Acetates; Adult; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; g

2002
Central post-stroke pain syndrome: yet another use for gabapentin?
    American journal of physical medicine & rehabilitation, 2002, Volume: 81, Issue:9

    Topics: Acetates; Activities of Daily Living; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxyli

2002
[Edematous syndrome and alithiasic cholecystitis induced by gabapentin].
    Presse medicale (Paris, France : 1983), 2002, Oct-12, Volume: 31, Issue:33

    Topics: Acetates; Adult; Amines; Anticonvulsants; Cholecystitis; Cyclohexanecarboxylic Acids; Edema; Epileps

2002
[Recognizing the "neck-tongue" syndrome].
    Presse medicale (Paris, France : 1983), 2003, Feb-01, Volume: 32, Issue:4

    Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Arthritis; Cervical Vertebrae; Cyclohexaneca

2003
[Case report on a patient with SUNCT-syndrome].
    Schmerz (Berlin, Germany), 2003, Volume: 17, Issue:2

    Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin

2003
[THE INFLUENCE OF GAMMA-AMINO-BETA-HYDROXYBUTYRIC ACID (GABOB) ON THE NEUROGENIC MANIFESTATIONS OF HYPERTHYROID SYNDROMES].
    La Clinica terapeutica, 1964, May-31, Volume: 29

    Topics: Aminobutyrates; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Hyperthyroidism; Neurologic Manif

1964
Chronic pain syndrome after laparoscopic radical nephrectomy.
    The Journal of urology, 2003, Volume: 170, Issue:5

    Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Carcinoma, Renal Cell; Carcinoma, Transition

2003
[Anticonvulsant hypersensitivity syndrome].
    Orvosi hetilap, 2004, Aug-08, Volume: 145, Issue:32

    Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Eruptions; Drug

2004
Neurontin for Charles Bonnet Syndrome.
    Journal of the American Geriatrics Society, 2006, Volume: 54, Issue:9

    Topics: Amines; Central Nervous System Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A

2006
Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Anticonvulsants; Antidepressive A

2006
Paroxysmal autonomic instability with dystonia.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2007, Volume: 17, Issue:6

    Topics: Adult; Amines; Autonomic Nervous System Diseases; Benzodiazepines; Brain Injuries; Cyclohexanecarbox

2007
Acupuncture, ketamine and piriformis syndrome--a case report from palliative care.
    Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2007, Volume: 25, Issue:3

    Topics: Acupuncture Therapy; Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Gab

2007
Case reports: red scrotal syndrome: a localized phenotypical expression of erythromelalgia.
    Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:9

    Topics: Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Erythromelalgia; Gabapentin;

2007
Considerations for general anesthesia combined with epidural anesthesia in a patient with stiff-person syndrome.
    Journal of anesthesia, 2007, Volume: 21, Issue:4

    Topics: Aged; Anesthesia, Epidural; Anesthesia, General; gamma-Aminobutyric Acid; Humans; Male; Muscle Rigid

2007
Gabapentin for painful legs and moving toes syndrome.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:23

    Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2007
Experimental autoimmune prostatitis induces chronic pelvic pain.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 294, Issue:4

    Topics: Amines; Analgesics; Anesthetics, Local; Animals; Autoimmune Diseases; Chronic Disease; Cyclohexaneca

2008
Cerebellar cognitive affective syndrome associated with topiramate.
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:5

    Topics: Amines; Anticonvulsants; Carbamazepine; Cerebellar Diseases; Cerebellum; Cognition Disorders; Cycloh

2008
Mechanistic studies on the high pressure neurological syndrome.
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 1984, Jan-07, Volume: 304, Issue:1118

    Topics: Animals; Atmospheric Pressure; Biogenic Amines; Biomechanical Phenomena; Central Nervous System Dise

1984
Specific effects of drugs at pressure: animal investigations.
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 1984, Jan-07, Volume: 304, Issue:1118

    Topics: Amino Acids; Anesthetics; Animals; Anticonvulsants; Atmospheric Pressure; Catecholamines; Central Ne

1984
Four biochemically different types of dominantly inherited olivopontocerebellar atrophy.
    Advances in neurology, 1984, Volume: 41

    Topics: Adult; Aged; Amino Acids; Aspartic Acid; Brain Chemistry; Cerebellar Ataxia; gamma-Aminobutyric Acid

1984
[Lumbar cerebrospinal fluid levels of GABA, HVA and 5HIAA in various patients with choreic movement and effects with isoniazid treatment].
    No to shinkei = Brain and nerve, 1983, Volume: 35, Issue:5

    Topics: Acanthocytes; Adult; Aged; Atrophy; Brain Diseases; Chorea; gamma-Aminobutyric Acid; Homovanillic Ac

1983
Increased GABA receptor binding in dominantly-inherited cerebellar ataxias.
    Brain research, 1983, Jun-20, Volume: 269, Issue:2

    Topics: Cerebellar Ataxia; Cerebellar Cortex; Cerebellar Nuclei; gamma-Aminobutyric Acid; Genes, Dominant; H

1983
Syndrome of continuous muscle-fiber activity: increased CSF GABA and effect of dantrolene.
    Neurology, 1983, Volume: 33, Issue:4

    Topics: Adolescent; Dantrolene; Electromyography; Female; gamma-Aminobutyric Acid; H-Reflex; Humans; Myotoni

1983
[Convulsive syndrome in DPT vaccination (a clinico-experimental study)].
    Pediatriia, 1983, Issue:5

    Topics: Adsorption; Animals; Central Nervous System; Child, Preschool; Diphtheria Toxoid; Drug Combinations;

1983
[Selective action of metabolic drug therapy in mentally retarded children].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1980, Volume: 80, Issue:3

    Topics: Child; gamma-Aminobutyric Acid; Humans; Intellectual Disability; Pantothenic Acid; Piracetam; Pyrith

1980
[Use of metabolically active preparations to study mild forms of mental deficiency].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1980, Volume: 80, Issue:3

    Topics: Child; Diagnosis, Differential; Female; gamma-Aminobutyric Acid; Humans; Intellectual Disability; Ma

1980
Vigabatrin monotherapy in resistant neonatal seizures.
    Seizure, 1995, Volume: 4, Issue:1

    Topics: Agenesis of Corpus Callosum; Anticonvulsants; Atrophy; Brain; Cerebral Cortex; Dose-Response Relatio

1995
Insulin resistance syndrome: defective GABA neuromodulation as a possible hereditary pathogenetic factor (the 'GABA hypothesis').
    Medical hypotheses, 1993, Volume: 40, Issue:4

    Topics: Animals; Brain; Cardiovascular Diseases; gamma-Aminobutyric Acid; Genetic Diseases, Inborn; Humans;

1993
Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin.
    Neurology, 1996, Volume: 46, Issue:3

    Topics: Acetates; Adolescent; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; ga

1996
Role of vigabatrin and lamotrigine in treatment of childhood epileptic syndromes.
    Epilepsia, 1998, Volume: 39, Issue:8

    Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination;

1998
A case of myokymia-cramp syndrome successfully treated with gabapentin.
    Acta neurologica Scandinavica, 1998, Volume: 98, Issue:6

    Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Extremities; Fasciculation; Gabapentin; gamma-Aminobu

1998
SUNCT syndrome responsive to gabapentin (Neurontin).
    Cephalalgia : an international journal of headache, 2000, Volume: 20, Issue:5

    Topics: Acetates; Amines; Analgesics; Conjunctival Diseases; Cyclohexanecarboxylic Acids; Gabapentin; gamma-

2000
Malignant appearing cachexia in an older patient with Bruns-Garland syndrome.
    Journal of the American Geriatrics Society, 2000, Volume: 48, Issue:12

    Topics: Acetates; Aged; Amines; Analgesics; Cachexia; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2

2000
Charles Bonnet's syndrome: complete remission of complex visual hallucinations treated by gabapentin.
    Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 70, Issue:6

    Topics: Acetates; Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Am

2001
Abnormalities in neurotransmitter amino acids in dominantly inherited cerebellar disorders.
    Advances in neurology, 1978, Volume: 21

    Topics: Amino Acids; Aspartic Acid; Atrophy; Brain Chemistry; Cerebellar Cortex; Cerebellar Diseases; Cerebe

1978
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
    Annals of neurology, 1979, Volume: 6, Issue:6

    Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate

1979
[Pathogenesis of stereotyped behavior].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1979, Volume: 79, Issue:9

    Topics: Animals; Behavior; Caudate Nucleus; Diazepam; Disease Models, Animal; gamma-Aminobutyric Acid; Halop

1979
[Role of biogenic amines in the pathogenesis of intellectual disorders in children with minimal psychoorganic syndromes].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1978, Volume: 78, Issue:10

    Topics: Attention Deficit Disorder with Hyperactivity; Catecholamines; Child; Dihydroxyphenylalanine; Electr

1978
Elevation of brain GABA concentrations with amino-oxyacetic acid; effect on the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats.
    Journal of neural transmission, 1976, Volume: 39, Issue:1-2

    Topics: Acetates; Aminobutyrates; Aminooxyacetic Acid; Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Hu

1976
Low cerebrospinal fluid concentration of free gamma-aminobutyric acid in startle disease.
    Lancet (London, England), 1992, Jul-11, Volume: 340, Issue:8811

    Topics: Clonazepam; Electroencephalography; Female; gamma-Aminobutyric Acid; Humans; Infant, Newborn; Phenob

1992
Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.
    Nature, 1990, Sep-13, Volume: 347, Issue:6289

    Topics: Animals; Animals, Newborn; Autoantibodies; Autoantigens; Autoimmunity; Brain; Diabetes Mellitus, Exp

1990
Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen.
    Italian journal of neurological sciences, 1990, Volume: 11, Issue:6

    Topics: Baclofen; Causalgia; Clonazepam; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans;

1990
Cerebrospinal fluid values for monoamine metabolites, gamma-aminobutyric acid, and other amino compounds in Rett syndrome.
    The Journal of pediatrics, 1988, Volume: 112, Issue:2

    Topics: Adolescent; Biogenic Amines; Brain Diseases; Child; Child Behavior Disorders; Child, Preschool; Deve

1988
[Progabide treatment of a case of the syndrome of painful legs and moving toes].
    Revue neurologique, 1985, Volume: 141, Issue:5

    Topics: Adult; Female; gamma-Aminobutyric Acid; Humans; Leg; Middle Aged; Movement Disorders; Pain; Receptor

1985
[Stiff-man syndrome and type I diabetes mellitus: a common autoimmune pathogenesis?].
    Annali dell'Istituto superiore di sanita, 1988, Volume: 24, Issue:4

    Topics: Antibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Epilepsy; gamma-Aminobutyric Acid; Gluta

1988
Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus.
    The New England journal of medicine, 1988, Apr-21, Volume: 318, Issue:16

    Topics: Autoantibodies; Autoimmune Diseases; Brain; Diabetes Mellitus, Type 1; Epilepsy; Female; gamma-Amino

1988
GABA levels in cerebrospinal fluid of patients with epilepsy.
    Folia psychiatrica et neurologica japonica, 1985, Volume: 39, Issue:4

    Topics: Adult; Cerebellar Ataxia; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Female; gamma-Aminobutyr

1985
[Syndrome involving the extrapyramidal motor systems and their drug treatment].
    Fortschritte der Medizin, 1974, Aug-08, Volume: 92, Issue:22

    Topics: Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dihydroxyphenylalanine; gamma-Aminobutyric

1974